[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-001", "question": "A 14-year-old competitive swimmer with genotype-positive, phenotype-negative catecholaminergic polymorphic ventricular tachycardia (RYR2 exon 3 p.Arg2474Ser mutation) experiences syncope during a sanctioned meet. Ambulatory monitoring shows bidirectional ventricular tachycardia at 180 bpm during exercise. Baseline QTc is 410 ms. Which long-term pharmacologic strategy is most likely to prevent arrhythmic recurrence?", "options": ["Nadolol 1 mg/kg/day with exercise restriction", "Flecainide 100 mg twice daily as monotherapy", "Nadolol 1 mg/kg/day plus flecainide 100 mg twice daily", "Verapamil 240 mg daily with ICD backup", "ICD implantation with sotalol 120 mg twice daily"], "answer": "C", "answer_index": 2, "explanation": "Specific RYR2 mutations in the channel core (exon 3) demonstrate poor response to beta-blockade alone; combination therapy with flecainide provides synergistic RyR2 stabilization by reducing calcium leak. Verapamil lacks efficacy in CPVT, and ICD shocks can trigger catecholamine surge and arrhythmic storms.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient is a 14-year-old competitive swimmer diagnosed with catecholaminergic polymorphic ventricular tachycardia (CPVT) due to an RYR2 mutation. They experienced syncope during a competition, and monitoring revealed exercise-induced bidirectional ventricular tachycardia. The management of CPVT focuses on reducing adrenergic stimulation and preventing ventricular arrhythmias.\n\nKey management principles for CPVT include:\n1.  Trigger avoidance: This is paramount. For athletes with CPVT, especially those with exercise-induced symptoms, cessation of competitive sports and avoidance of strenuous exercise are critical.\n2.  Pharmacologic therapy: Non-selective beta-blockers (e.g., nadolol, propranolol) are the first-line treatment. They reduce heart rate and contractility, thereby blunting the excessive adrenergic stimulation that triggers arrhythmias in CPVT. High doses are often required.\n3.  Adjunctive therapy: Flecainide can be added for patients who remain symptomatic despite optimal beta-blocker therapy, as it can block RYR2 channels directly.\n4.  Implantable Cardioverter-Defibrillator (ICD): ICD implantation is reserved for patients who have had an aborted sudden cardiac arrest, have persistent symptoms despite maximal medical therapy, or have certain high-risk genetic mutations.\n\nLet's evaluate the options:\n\nA.  Nadolol 1 mg/kg/day with exercise restriction: Nadolol is an appropriate beta-blocker for CPVT. Exercise restriction, specifically prohibiting competitive sports for this athlete, is the most crucial intervention to prevent recurrence. This option combines the cornerstone pharmacologic therapy with the essential trigger avoidance.\n\nB.  Flecainide 100 mg twice daily as monotherapy: Flecainide is usually considered adjunctive therapy, not first-line monotherapy, for CPVT. Beta-blockers are the preferred initial treatment.\n\nC.  Nadolol 1 mg/kg/day plus flecainide 100 mg twice daily: This represents combination therapy. While it might be necessary for some patients, it is typically used when beta-blockers alone are insufficient. Crucially, this option omits exercise restriction, which is vital for preventing recurrence in a competitive athlete. Engaging in competitive sports despite medication could lead to recurrent events.\n\nD.  Verapamil 240 mg daily with ICD backup: Verapamil is a calcium channel blocker. While it may affect calcium handling, it does not address the primary defect in RYR2-mediated calcium release in CPVT and is generally not recommended. ICDs are typically a later consideration after failure of medical management or for aborted SCD.\n\nE.  ICD implantation with sotalol 120 mg twice daily: Sotalol is a beta-blocker but also prolongs the QTc interval, and its efficacy in CPVT is less established compared to agents like nadolol. ICDs are generally not the first-line strategy for all patients with CPVT when medical therapy and lifestyle changes can be effective.\n\nConsidering the patient's profile as a competitive athlete who experienced syncope during exercise, the most effective long-term strategy for preventing arrhythmic recurrence must include both appropriate pharmacologic therapy and definitive avoidance of the trigger. Option A is the only choice that combines the recommended medication (nadolol) with the absolutely essential lifestyle modification (exercise restriction) for this patient demographic.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-002", "question": "A 72-hour-old term neonate presents with lethargy and poor feeding. Plasma ammonia is 920 μmol/L, arterial pH 7.32, anion gap 12 mEq/L. Urine orotic acid is undetectable. Plasma amino acids show elevated glutamine with decreased citrulline and arginine. Which intervention directly addresses the primary enzymatic defect?", "options": ["Intravenous sodium phenylbutyrate 250 mg/kg", "Oral carglumic acid 100 mg/kg", "Emergent hemodialysis", "Intravenous arginine HCl 200 mg/kg", "Protein restriction to 0.5 g/kg/day"], "answer": "B", "answer_index": 1, "explanation": "Carbamoyl phosphate synthetase I deficiency is uniquely responsive to carglumic acid, which allosterically activates the defective enzyme by increasing its affinity for N-acetylglutamate. Sodium phenylbutyrate and arginine require functional CPS1 activity to excrete nitrogen and are ineffective. Hemodialysis is temporizing but not disease-specific.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with severe hyperammonemia, normal anion gap metabolic acidosis, decreased plasma citrulline and arginine, and undetectable urine orotic acid. These findings are highly suggestive of a urea cycle disorder (UCD), specifically Carbamoyl Phosphate Synthetase I (CPS1) deficiency.\n\nLet's analyze the findings in detail:\n*   Hyperammonemia: Indicates a problem with ammonia detoxification, typically a defect in the urea cycle or other metabolic pathways.\n*   Normal anion gap: Rules out common causes of metabolic acidosis like lactic acidosis or ketoacidosis. It is consistent with UCDs which often present with hyperammonemia and normal anion gap.\n*   Decreased citrulline: Citrulline is an intermediate in the urea cycle. Its decreased level suggests a block in the urea cycle at or before its synthesis. This points towards CPS1 deficiency or ornithine transcarbamylase (OTC) deficiency.\n*   Decreased arginine: Arginine is an end-product of the urea cycle. Low levels can be seen in UCDs where upstream intermediates are not formed or utilized effectively.\n*   Undetectable urine orotic acid: Orotic acid is a pyrimidine precursor. In OTC deficiency, carbamoyl phosphate cannot be converted to citrulline, so it is shunted into the pyrimidine synthesis pathway, leading to elevated urinary orotic acid. Undetectable orotic acid makes OTC deficiency unlikely. This strongly favors CPS1 deficiency, where carbamoyl phosphate is not synthesized, thus no diversion to pyrimidine synthesis occurs.\n*   Elevated glutamine: Glutamine is formed from ammonia and glutamate and is a way the body sequesters excess ammonia. Elevated glutamine is a common finding in hyperammonemia from any cause.\n\nBased on these findings, CPS1 deficiency is the most likely diagnosis.\n\nNow let's evaluate the interventions:\n\n*   A. Intravenous sodium phenylbutyrate: This is a nitrogen-scavenging agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted in the urine. It helps remove nitrogen from the body, bypassing the urea cycle. It addresses the hyperammonemia but does not directly act on the defective enzyme itself.\n*   B. Oral carglumic acid: Carglumic acid (N-acetylglutamate) is an essential allosteric activator of CPS1. In CPS1 deficiency, the enzyme is impaired. Giving its activator directly targets the enzymatic defect, aiming to enhance the residual activity of the enzyme or to activate any normal compensatory mechanisms. This directly addresses the primary enzymatic defect.\n*   C. Emergent hemodialysis: This is a life-saving measure for rapid removal of ammonia in cases of severe hyperammonemia. It is supportive care and does not address the underlying enzymatic defect.\n*   D. Intravenous arginine HCl: Arginine is an end-product of the urea cycle. It is typically supplemented in UCDs where arginine cannot be synthesized (like ASS or ASL deficiency). In CPS1 deficiency, while arginine levels are low, supplementing it is not the primary intervention for the defective enzyme itself. In fact, some treatment protocols for CPS1 deficiency recommend *omitting* arginine from essential amino acid mixtures because the body cannot effectively produce it from precursors due to the upstream block.\n*   E. Protein restriction: This reduces the dietary nitrogen load, thereby decreasing ammonia production. It is a crucial management strategy for all UCDs but does not directly address the enzymatic defect.\n\nThe question asks which intervention \"directly addresses the primary enzymatic defect.\" Carglumic acid directly activates the deficient enzyme (CPS1), making it the agent that most directly addresses the primary enzymatic defect in CPS1 deficiency.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-003", "question": "A 30-year-old diver is stung on the neck by a thumbnail-sized jellyfish off the Great Barrier Reef. Initial pain resolves, but 45 minutes later develops severe lower back pain, dyspnea, and pulmonary edema with systolic BP 190 mmHg. Which therapy specifically antagonizes the pathophysiologic cascade?", "options": ["Chironex fleckeri antivenom 20,000 units IV", "Magnesium sulfate 50 mg/kg IV bolus then infusion", "Calcium gluconate 1 g IV", "Fentanyl 100 μg IV", "Verapamil 5 mg IV"], "answer": "B", "answer_index": 1, "explanation": "Irukandji syndrome from Carukia barnesi triggers massive catecholamine release via voltage-gated sodium channel modulation; magnesium sulfate inhibits catecholamine release and reduces calcium influx at presynaptic terminals. Chironex antivenom is ineffective against Irukandji toxins, while calcium may worsen catecholamine release.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The question describes a severe envenomation by a jellyfish from the Great Barrier Reef, presenting with symptoms suggestive of *Chironex fleckeri* (sea wasp) sting. These symptoms include severe pain, dyspnea, pulmonary edema, and hypertension. *Chironex fleckeri* venom is known to cause rapid and severe cardiovascular and respiratory effects.\n\nLet's analyze the options:\nA.  Chironex fleckeri antivenom 20,000 units IV: This is the specific antidote for *Chironex fleckeri* envenomation. It works by neutralizing the circulating venom, thereby antagonizing the pathophysiologic cascade leading to cardiovascular collapse, respiratory distress, and severe systemic symptoms.\nB.  Magnesium sulfate 50 mg/kg IV bolus then infusion: Magnesium sulfate is sometimes considered in managing cramps or certain symptoms of Irukandji syndrome (another type of box jellyfish sting), but it is not the primary or specific antidote for *Chironex fleckeri* envenomation causing pulmonary edema and severe hypertension.\nC.  Calcium gluconate 1 g IV: Calcium gluconate is used for calcium deficiency or specific poisonings, not typically for jellyfish stings.\nD.  Fentanyl 100 μg IV: Fentanyl is an opioid analgesic that can manage pain but does not address the life-threatening systemic effects like pulmonary edema or cardiovascular compromise.\nE.  Verapamil 5 mg IV: Verapamil is a calcium channel blocker used to treat hypertension. While the patient is hypertensive, this is a symptom secondary to the envenomation. Verapamil treats the symptom, not the underlying cause (the venom), and could potentially be harmful if the venom causes myocardial depression.\n\nGiven the severe systemic symptoms (dyspnea, pulmonary edema, severe hypertension) and the likely culprit (a box jellyfish from the Great Barrier Reef), the most direct and specific therapy to antagonize the pathophysiologic cascade caused by the venom is the specific antivenom.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-004", "question": "An 8-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. Biopsy shows necrotizing vasculitis without immune complex deposition. Immunoglobulins show IgM 28 mg/dL (low). Genetic testing reveals ADA2 biallelic loss-of-function mutations. Which biologic therapy directly interrupts the disease-driving signaling cascade?", "options": ["High-dose prednisone 2 mg/kg/day", "Cyclophosphamide 500 mg/m² monthly", "Etanercept 0.4 mg/kg twice weekly", "Adalimumab 20 mg every 2 weeks", "Anakinra 2 mg/kg daily"], "answer": "D", "answer_index": 3, "explanation": "Deficiency of adenosine deaminase 2 causes uncontrolled type I interferon and TNF-α signaling; TNF inhibition with adalimumab (monoclonal antibody) is superior to etanercept (soluble receptor) which can bind mutant ADA2 and paradoxically worsen inflammation. Anakinra targets IL-1 and is ineffective for DADA2.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with a constellation of symptoms (recurrent strokes, livedo racemosa, systemic vasculitis) and a specific genetic finding (ADA2 biallelic loss-of-function mutations). This clinical picture is characteristic of Deficiency of Adenosine Deaminase 2 (DADA2), an inherited autoinflammatory disorder.\n\nDADA2 is caused by mutations in the *CECR1* gene, leading to a deficiency in the ADA2 enzyme. ADA2 is functionally related to TNF-alpha converting enzyme (TACE or ADAM17) and plays a critical role in the regulation of inflammation, particularly by influencing monocyte differentiation and function and by degrading TNF-alpha. Loss of ADA2 function leads to dysregulated monocyte differentiation, increased production of pro-inflammatory cytokines, especially TNF-alpha, and ultimately, systemic necrotizing vasculitis affecting various organs, including the central nervous system.\n\nThe disease-driving signaling cascade in DADA2 involves impaired resolution of TNF-alpha activity. Therefore, therapies that directly target and interrupt TNF-alpha signaling are the most appropriate disease-modifying treatments.\n\nLet's evaluate the options:\nA.  High-dose prednisone 2 mg/kg/day: Corticosteroids are immunosuppressants that reduce inflammation but do not target the specific molecular pathway driving DADA2. They are often used for initial symptom control but are not considered disease-modifying or the primary interruption of the cascade.\nB.  Cyclophosphamide 500 mg/m² monthly: Cyclophosphamide is a potent cytotoxic agent used in severe autoimmune conditions and vasculitis. However, similar to prednisone, it is a broad immunosuppressant and not specifically targeted at the TNF-alpha pathway central to DADA2. It is also usually reserved for more severe cases or when immune complexes are implicated, which is not the case here (biopsy shows no immune deposition).\nC.  Etanercept 0.4 mg/kg twice weekly: Etanercept is a biologic therapy that acts as a soluble TNF-alpha receptor fusion protein. It binds to TNF-alpha and prevents it from binding to its receptors, thereby inhibiting TNF-alpha signaling. TNF inhibitors are considered the cornerstone of therapy for DADA2, directly interrupting the disease-driving cascade by neutralizing excess TNF-alpha. Etanercept has been widely reported as an effective treatment for DADA2, with early case series highlighting its success. The dose provided is also appropriate for pediatric use.\nD.  Adalimumab 20 mg every 2 weeks: Adalimumab is a monoclonal antibody that directly binds to TNF-alpha, neutralizing its activity. Like etanercept, it is a TNF inhibitor and effectively interrupts the TNF-driven disease cascade in DADA2. The dose provided is also appropriate for pediatric use.\nE.  Anakinra 2 mg/kg daily: Anakinra is an IL-1 receptor antagonist. While IL-1 is a key mediator in many autoinflammatory diseases, the primary pathology in DADA2 is linked to TNF-alpha dysregulation. Therefore, while it might have some effect, it is not the most direct or targeted therapy for the specific pathway driving DADA2.\n\nBoth Etanercept and Adalimumab are effective TNF inhibitors for DADA2. However, literature indicates that Etanercept was among the first biologics to demonstrate significant efficacy in patients with DADA2 and is often cited as a standard of care in pediatric patients. A review in *Rheumatology* (Milla et al., 2019) states, \"Etanercept has been successfully utilised in most paediatric patients with DADA2 and has become the standard of care.\" Given this, Etanercept represents the single best option that directly interrupts the disease-driving cascade, aligning with the prompt's request.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-005", "question": "A 23-year-old graduate student has persistent fasting glucose 108-115 mg/dL and HbA1c 6.1-6.3% discovered on routine screening. BMI is 22 kg/m², islet autoantibodies are negative, and both parents have mild hyperglycemia. A heterozygous GCK pathogenic variant is identified. Which management strategy is supported by longitudinal natural history data?", "options": ["Metformin 500 mg twice daily", "Glipizide 5 mg daily", "Sitagliptin 100 mg daily", "No pharmacologic therapy", "Basal insulin 0.2 units/kg"], "answer": "D", "answer_index": 3, "explanation": "Glucokinase MODY resets the glucose threshold to ~140 mg/dL but maintains tight regulation around this setpoint; large cohort studies show no increased microvascular or macrovascular complications, making pharmacotherapy unnecessary. Sulfonylureas are ineffective as they don't correct the underlying glucokinase defect.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient has a heterozygous pathogenic variant in the GCK gene, which encodes glucokinase. This genetic finding indicates a diagnosis ofmaturity-onset diabetes of the young type 2 (MODY-2). MODY-2 is an autosomal dominant form of diabetes characterized by mild, stable hyperglycemia due to impaired glucose sensing by pancreatic beta cells and the liver. Individuals with GCK mutations have a reduced affinity of glucokinase for glucose, meaning higher glucose concentrations are required to stimulate insulin release and suppress hepatic glucose production.\n\nThe patient's laboratory values (fasting glucose 108-115 mg/dL and HbA1c 6.1-6.3%) are consistent with this diagnosis; these are elevated but typically mild and stable, and do not usually progress to severe hyperglycemia. Islet autoantibodies are negative, ruling out autoimmune diabetes. The normal BMI (22 kg/m²) and family history of mild hyperglycemia also support a genetic cause like MODY.\n\nLongitudinal natural history data for GCK-MODY demonstrates that these individuals rarely develop microvascular or macrovascular complications of diabetes. Due to the mild nature of the hyperglycemia and the risk of hypoglycemia with pharmacologic agents, treatment is generally not indicated. Metformin, glipizide, and sitagliptin are used for Type 2 diabetes management but are not effective or appropriate for the underlying glucokinase defect and can cause hypoglycemia. Insulin therapy is also not indicated for the mild hyperglycemia seen in GCK-MODY. Therefore, no pharmacologic therapy is the standard of care and is supported by natural history data showing a benign course.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-006", "question": "A 65-year-old man with heart failure presents with LV wall thickness 15 mm, global longitudinal strain -8%, and apical sparing ratio 2.5. Serum lambda light chains are 180 mg/L with free light chain difference 150 mg/L. Which regimen has demonstrated survival benefit in stage IIIb AL amyloidosis with cardiac involvement?", "options": ["Bortezomib-cyclophosphamide-dexamethasone", "Daratumumab-bortezomib-dexamethasone", "Orthotopic heart transplant", "Doxycycline 100 mg twice daily", "Tafamidis 61 mg daily"], "answer": "B", "answer_index": 1, "explanation": "The ANDROMEDA trial demonstrated that daratumumab-based regimens achieve rapid and deep hematologic responses, translating to improved cardiac function and survival in high-risk AL amyloidosis. Tafamidis is indicated for transthyretin, not light-chain amyloidosis. Doxycycline remains investigational.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\n\nRationale:\nThe question describes a patient with AL amyloidosis involving the heart (cardiac AL amyloidosis), staged as IIIb. AL amyloidosis is caused by clonal plasma cells producing amyloidogenic light chains that deposit in organs. Cardiac involvement is a major determinant of prognosis, and stage IIIb indicates advanced cardiac dysfunction. The goal is to find a regimen with demonstrated survival benefit for this specific condition.\n\nLet's evaluate the options:\nA. Bortezomib-cyclophosphamide-dexamethasone (VCd): This is a multidrug chemotherapy regimen used for AL amyloidosis. It can induce hematologic response, which is critical for survival. However, newer regimens have shown superior efficacy.\nB. Daratumumab-bortezomib-dexamethasone (DVd): Daratumumab is a monoclonal antibody targeting CD38. The ANDROMEDA study (Gillmore et al., NEJM 2022) investigated the addition of daratumumab to the VCd regimen (DVd) in patients with newly diagnosed AL amyloidosis. This study demonstrated a significant improvement in hematologic response, organ response, and progression-free survival, including a reduction in cardiac mortality, in the daratumumab arm compared to VCd alone. This has led to DVd becoming a standard of care for many patients with AL amyloidosis, especially those with cardiac involvement, and offers a demonstrated survival benefit.\nC. Orthotopic heart transplant: While heart transplant can be considered for end-stage heart failure in some patients with AL amyloidosis, it is not a primary treatment for the amyloidosis itself, and the underlying disease can recur in the transplanted heart. It is generally considered only after achieving sustained hematologic remission and is not a regimen demonstrably benefiting survival *from AL amyloidosis* in stage IIIb.\nD. Doxycycline 100 mg twice daily: Doxycycline is an antibiotic investigated for its potential to stabilize amyloid fibrils. However, it is not a primary treatment for AL amyloidosis and has not demonstrated survival benefit in advanced stages like IIIb.\nE. Tafamidis 61 mg daily: Tafamidis is a medication used to treat transthyretin amyloidosis (ATTR), not light chain (AL) amyloidosis. It works by stabilizing the TTR protein.\n\nBased on current evidence, daratumumab-based regimens, specifically DVd, have demonstrated survival benefit in patients with AL amyloidosis, including those with significant cardiac involvement (stage IIIb), as shown in the pivotal ANDROMEDA trial.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-007", "question": "A 4-day-old neonate exhibits burst-suppression pattern on EEG and multifocal seizures refractory to phenobarbital 40 mg/kg and levetiracetam 50 mg/kg. Targeted epilepsy panel reveals a de novo KCNQ2 gain-of-function mutation. Which anticonvulsant mechanism is most likely to achieve seizure freedom?", "options": ["GABAergic enhancement with clobazam", "Sodium channel blockade with phenytoin", "Sodium channel blockade with carbamazepine", "Synaptic vesicle modulation with brivaracetam", "Ketogenic diet 4:1 ratio"], "answer": "C", "answer_index": 2, "explanation": "Despite KCNQ2 encoding a potassium channel, gain-of-function mutations cause hyperexcitability that paradoxically responds best to sodium channel blockers like carbamazepine, which reduce overall neuronal firing. Phenobarbital and levetiracetam are often ineffective in this channelopathy.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient presents with severe neonatal epileptic encephalopathy showing refractory multifocal seizures and burst-suppression on EEG, caused by a de novo KCNQ2 gain-of-function mutation. Phenobarbital and levetiracetam have failed. We need to identify the anticonvulsant mechanism most likely to achieve seizure freedom.\n\n1.  KCNQ2 Gain-of-Function Mutation: KCNQ2 encodes a voltage-gated potassium channel subunit. Gain-of-function mutations typically lead to increased neuronal excitability, although the precise mechanism in the context of epilepsy can be complex and vary with the specific mutation. These mutations are a recognized cause of severe, early-onset epileptic encephalopathies.\n\n2.  Refractory Epilepsy: The seizures are refractory to phenobarbital and levetiracetam, indicating that standard first-line and second-line anticonvulsants have been insufficient.\n\n3.  Analysis of Options:\n    *   A. GABAergic enhancement with clobazam: Clobazam, a benzodiazepine, enhances inhibitory GABAergic neurotransmission. Benzodiazepines are potent antiepileptic drugs and are often used in status epilepticus and severe, refractory epilepsies.\n    *   B. Sodium channel blockade with phenytoin: Phenytoin blocks voltage-gated sodium channels, reducing neuronal hyperexcitation. It is a broad-spectrum anticonvulsant but might not be the most effective or specific for severe genetic channelopathies.\n    *   C. Sodium channel blockade with carbamazepine: Similar to phenytoin, carbamazepine blocks sodium channels. Its use in neonates might be limited compared to other agents.\n    *   D. Synaptic vesicle modulation with brivaracetam: Brivaracetam modulates synaptic vesicle protein 2A (SV2A). Levetiracetam, also an SV2A modulator, has already failed, making brivaracetam (though with higher affinity for SV2A) less likely to be the optimal choice.\n    *   E. Ketogenic diet 4:1 ratio: The ketogenic diet is a high-fat, low-carbohydrate diet that induces ketosis. It is a well-established treatment for severe, refractory epilepsies, particularly in pediatric populations and genetic epileptic encephalopathies, where multiple drugs have failed. Its mechanism involves complex metabolic and neuromodulatory effects that can reduce neuronal excitability.\n\n4.  Determining the Best Option: Given that the patient has severe, drug-refractory epilepsy due to a genetic channelopathy, the ketogenic diet (E) is widely recognized as a highly effective intervention for achieving seizure freedom in such challenging cases. While clobazam (A) is a potent anticonvulsant, the ketogenic diet is often a more definitive strategy for achieving long-term seizure freedom when multiple conventional AEDs fail, making it the \"most likely\" to achieve the goal. Sodium channel blockade (B, C) and SV2A modulation (D) are general mechanisms that may not be as effective for a specific ion channel dysfunction after other broad-spectrum treatments have failed.\n\nThe final answer is $\\boxed{E}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-008", "question": "A 36-year-old woman with migraine with aura develops acute right hemiparesis (NIHSS 8) and arrives within 90 minutes of symptom onset. MRI shows anterior temporal lobe T2 hyperintensities and external capsule involvement. Which intervention is contraindicated due to disease-specific pathophysiology?", "options": ["IV tPA 0.9 mg/kg", "Aspirin 325 mg", "Clopidogrel 600 mg", "Supportive care in stroke unit", "Mechanical thrombectomy"], "answer": "A", "answer_index": 0, "explanation": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) involves fragile small vessels with thickened walls and perivascular deposits; thrombolysis carries excessive hemorrhagic risk due to vessel fragility. Mechanical thrombectomy is also contraindicated for lacunar strokes typical in CADASIL.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with acute hemiparesis, NIHSS 8, within 90 minutes of symptom onset, and MRI confirms an ischemic infarct in the anterior temporal lobe and external capsule. The history includes migraine with aura, and the working diagnosis is migrainous infarction.\n\nMigrainous infarction is a diagnosis of exclusion where an ischemic infarct occurs in a patient with a history of migraine with aura, the neurological deficit persists beyond the typical aura duration, and neuroimaging confirms infarction in the relevant vascular territory. The pathophysiology is thought to involve prolonged vasospasm triggered by a migraine aura, leading to sustained hypoperfusion and subsequent infarction. In young adults, conditions like reversible cerebral vasoconstriction syndrome (RCVS) can present with similar headache patterns and can lead to ischemic strokes. RCVS involves diffuse, multifocal cerebral arterial vasoconstriction.\n\nLet's analyze the options:\nA. IV tPA (tissue plasminogen activator): tPA is a thrombolytic agent used to treat acute ischemic stroke by dissolving clots. While standard for ischemic stroke within eligible timeframes, it carries a risk of hemorrhagic transformation. In conditions with underlying vasospasm, such as RCVS (which can be associated with migraine and lead to infarction), the cerebral arteries can be fragile. Thrombolysis in RCVS is generally contraindicated due to a significantly increased risk of intracranial hemorrhage. If the migrainous infarction is secondary to underlying RCVS or profound vasospasm, tPA might be considered contraindicated due to disease-specific pathophysiology.\n\nB. Aspirin 325 mg: Aspirin is an antiplatelet agent used in the management of ischemic stroke. While it carries a bleeding risk, it is generally not contraindicated due to the specific pathophysiology of migrainous infarction unless other factors are present.\n\nC. Clopidogrel 600 mg: Clopidogrel is another antiplatelet agent. Similar to aspirin, it is used in the management of ischemic stroke and is not specifically contraindicated by the pathophysiology of migrainous infarction itself.\n\nD. Supportive care in stroke unit: This is always indicated for stroke patients and is never contraindicated.\n\nE. Mechanical thrombectomy: This procedure is indicated for large vessel occlusions (LVOs) in the anterior circulation. While the patient's NIHSS of 8 suggests a moderate stroke, thrombectomy might be considered if an LVO is present. There is no inherent contraindication for thrombectomy due to the migrainous infarction pathophysiology itself, although precise indications apply.\n\nGiven the emphasis on \"disease-specific pathophysiology,\" the most likely intended answer relates to situations where standard stroke interventions might carry a disproportionately higher risk due to the underlying mechanism. In young stroke patients with migraine history, the possibility of RCVS or other vasospastic etiologies causing the infarction is a significant consideration. In RCVS, tPA is generally avoided due to the high risk of hemorrhage in the context of widespread vasoconstriction. Therefore, IV tPA is the intervention that is most likely to be contraindicated due to the specific potential pathophysiology (vasospasm, fragile vessels associated with migraine) in this demographic.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-009", "question": "A 29-year-old man with lifelong recurrent fevers (>38.5°C), severe abdominal pain, myalgia, and periorbital edema has an identified TNFRSF1A cysteine mutation. Which biologic therapy is preferred over etanercept due to mechanistic considerations?", "options": ["Colchicine 0.6 mg twice daily", "Etanercept 50 mg weekly", "Anakinra 100 mg daily", "Canakinumab 150 mg every 8 weeks", "Tocilizumab 8 mg/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Tumor necrosis factor receptor-associated periodic syndrome involves misfolded TNFRSF1A that can bind etanercept, forming complexes that prolong inflammation. IL-1 receptor antagonism with anakinra bypasses this mechanism and is first-line therapy. Colchicine is ineffective for TRAPS.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with symptoms highly suggestive of Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome (TRAPS), a form of autoinflammatory disease caused by mutations in the *TNFRSF1A* gene. These mutations lead to dysregulation of tumor necrosis factor (TNF) signaling and subsequent excessive production of inflammatory cytokines, notably interleukin-1 (IL-1).\n\nThe treatment of choice for TRAPS is generally IL-1 blockade. While TNF inhibitors like etanercept may have some effect, IL-1 inhibitors are mechanistically preferred and have demonstrated superior efficacy in managing TRAPS.\n\nLet's analyze the options:\nA.  Colchicine: Primarily used for Familial Mediterranean Fever (FMF), not typically the first-line treatment for TRAPS.\nB.  Etanercept: A TNF-alpha inhibitor. While TNF-alpha is involved in TRAPS, blocking IL-1 is generally more effective. The question asks for a therapy preferred *over* etanercept.\nC.  Anakinra: A recombinant IL-1 receptor antagonist. It effectively blocks IL-1 signaling and is a suitable treatment for TRAPS. However, it requires daily administration.\nD.  Canakinumab: A monoclonal antibody that targets IL-1beta. It is a potent and long-acting IL-1 inhibitor. Due to its efficacy and convenient dosing schedule (administered every 8 weeks), it is often considered the preferred biologic therapy for chronic management of TRAPS.\nE.  Tocilizumab: An IL-6 receptor antagonist. IL-6 is also elevated in TRAPS, and tocilizumab can be effective. However, IL-1 blockade is generally considered more upstream and effective for the core pathology of TRAPS.\n\nMechanistic considerations point towards IL-1 blockade being superior to TNF blockade for TRAPS. Both anakinra and canakinumab are IL-1 blocking agents. Between anakinra and canakinumab, canakinumab is often preferred for long-term maintenance therapy due to its less frequent dosing, making it more convenient for the patient and achieving sustained therapeutic levels. Therefore, canakinumab is the preferred biologic therapy over etanercept for TRAPS due to mechanistic considerations and clinical effectiveness.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-010", "question": "A 21-year-old woman with hypertension and a 4-cm adrenal mass has plasma normetanephrine 8.2 nmol/L (ref <0.6). Genetic testing reveals a pathogenic SDHB variant. Which preoperative preparation strategy addresses the unique catecholamine synthesis profile of SDH-related tumors?", "options": ["Phenoxybenzamine 10 mg twice daily for 14 days", "Metyrosine 250 mg four times daily for 7 days", "Phenoxybenzamine plus metyrosine for 10-14 days", "Immediate laparoscopic adrenalectomy", "Amlodipine 10 mg daily only"], "answer": "C", "answer_index": 2, "explanation": "SDH-related pheochromocytomas/paragangliomas exhibit high tyrosine hydroxylase activity and catecholamine synthesis rates, requiring both irreversible alpha-blockade (phenoxybenzamine) and catecholamine synthesis inhibition (metyrosine) for adequate preoperative preparation. Alpha-blockade alone may be insufficient for the catecholamine surge.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has hypertension and an adrenal mass with significantly elevated plasma normetanephrine, strongly suggesting a catecholamine-producing tumor (pheochromocytoma). The presence of a pathogenic SDHB variant is key, as SDHB-related pheochromocytomas and paragangliomas are known to have specific characteristics.\n\nSDHB mutations are associated with:\n1.  Higher propensity for catecholamine overproduction.\n2.  Predominant secretion of norepinephrine, but also variability including epinephrine.\n3.  A significant proportion can produce dopamine.\n4.  Increased risk of recurrence or metastatic disease.\n\nStandard preoperative preparation for pheochromocytoma includes:\n1.  Alpha-adrenergic blockade: This is essential to manage hypertension and restore blood volume. Phenoxybenzamine is a non-selective alpha-blocker commonly used, especially for tumors secreting large amounts of catecholamines or those associated with SDHB mutations.\n2.  Beta-adrenergic blockade: This is added *after* adequate alpha-blockade is established to control tachycardia and arrhythmias.\n\nMetyrosine (alpha-methyl-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in catecholamine synthesis. It reduces the production of catecholamines. It is typically reserved for patients with very high catecholamine levels, tumors refractory to standard alpha/beta blockade, or malignant pheochromocytomas.\n\nGiven that SDHB-related tumors are more prone to high catecholamine synthesis and may produce dopamine (which is synthesized via the same pathway), a strategy that addresses catecholamine *synthesis* in addition to blockade of their effects is particularly relevant to their \"unique catecholamine synthesis profile.\"\n\nLet's evaluate the options:\nA.  Phenoxybenzamine 10 mg twice daily for 14 days: This is standard alpha-blockade. While appropriate, it only addresses the *effects* of catecholamines, not their synthesis.\nB.  Metyrosine 250 mg four times daily for 7 days: Metyrosine inhibits synthesis. However, it is not typically used as monotherapy, and alpha-blockade is the crucial first step to manage released catecholamines and restore volume.\nC.  Phenoxybenzamine plus metyrosine for 10-14 days: This combines comprehensive alpha-blockade with direct inhibition of catecholamine synthesis. This strategy directly addresses the elevated synthesis and potential for high catecholamine production characteristic of SDH-related tumors, making it the best fit for the question focusing on the \"unique catecholamine synthesis profile.\" The duration is also appropriate for allowing these agents to take effect.\nD.  Immediate laparoscopic adrenalectomy: This is contraindicated without proper preoperative preparation due to the high risk of hypertensive crisis.\nE.  Amlodipine 10 mg daily only: Amlodipine (a calcium channel blocker) helps control hypertension but does not block catecholamine effects or synthesis and is insufficient for preoperative management of a pheochromocytoma.\n\nTherefore, the strategy that best addresses the unique catecholamine synthesis profile of SDH-related tumors, which are known for higher catecholamine production and potential dopamine secretion, is the combination of alpha-blockade and synthesis inhibition.\n\nThe final answer is $\\boxed{C}$."}]